Page last updated: 2024-09-04

cyc 202 and a 443654

cyc 202 has been researched along with a 443654 in 2 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(a 443654)
Trials
(a 443654)
Recent Studies (post-2010) (a 443654)
979739343019

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)a 443654 (IC50)
cAMP-dependent protein kinase catalytic subunit alphaBos taurus (cattle)0.0165
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.0007
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)0.0152
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)0.051

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Bharate, SB; Raghuvanshi, R1

Other Studies

2 other study(ies) available for cyc 202 and a 443654

ArticleYear
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022